[Cannabidiol pharmacotherapy for delta-9-tetrahidrocannabinol dependence].
Federico Pavlovsky, Rafael Groisman, Ana Karina Hurtado, Luciana García
Vertex Revista Argentina de Psiquiatría October 10, 2022 DOI: 10.53680/vertex.v33i157.265 (opens in new tab)
Study at a glance
AI-extracted from the abstract| Characteristics | Review Peer reviewed |
|---|---|
| Interventions | Cannabidiol Tetrahydrocannabinol |
| Topics | Addiction Cannabis CBD |
| Keywords | Replacement therapy Cannabinoid Clinical trials |
| Key findings | The authors report that evidence on pharmacotherapy for cannabis use disorder is limited, but that a small number of animal and human trials of cannabinoids, especially cannabidiol and tetrahydrocannabinol, show reductions in days of use, withdrawal symptoms, and craving. They argue that larger trials with longer treatment periods are urgently needed. |
Abstract
Addictions are one of the most important health problems worldwide. Within these disorders, cannabis is one of the psychoactive substances with more burden of morbidity and mortality worldwide. The actual knowledge about the effectiveness of treatments for cannabis use disorders is unsatisfactory. This review aims to explore the evidence on cannabidiol for the treatment of cannabis use disorder. There are several clinical pharmacotherapy trials researching cannabis use disorders with limited evidence. A smaller number of trials in animal models and humans on the use of cannabinoids, especially Cannabidiol and Tetrahydrocannabinol to treat cannabis dependence show evidence of reduction in days of use, withdrawal symptoms and craving. New trials are under development, and there is an urgent need for trials with larger numbers of patients and longer treatment periods to support possible indications in the near future.
Comparable studies
Other narrative reviews on cannabis for addiction, most cited first.
| Study | Year | Design | Participants |
|---|---|---|---|
| The neuropsychopharmacology of cannabis: A review of human imaging studies | 2018 | Review | |
| Substance-Induced Psychoses: An Updated Literature Review General (substance-induced psychosis) | 2021 | Narrative review | |
| New psychoactive substances of natural origin: A brief review | 2017 | Review | |
| New Psychoactive Substances (NPS) – a Challenge for the Addiction Treatment Services | 2017 | Review | |
| Classic Psychedelics in Addiction Treatment: The Case for Psilocybin in Tobacco Smoking Cessation | 2022 | Review |
Citations in the library
Cites 3
- Inverted U-Shaped Dose-Response Curve of the Anxiolytic Effect of Cannabidiol during Public Speaking in Real Life Frontiers in Pharmacology May 11, 2017
- Cannabidiol versus risperidone for treatment of recent-onset psychosis with comorbid cannabis use: study protocol for a randomized controlled clinical trial BMC Psychiatry August 14, 2021
- The endocannabinoid system: emotion, learning and addiction. Addiction Biology June 2008